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Inhibition of c-kit receptor tyrosine kinase activity by STI 571,
a selective tyrosine kinase inhibitor
Michael C. Heinrich, Diana J. Griffith, Brian J. Druker, Cecily L. Wait, KristenA. Ott, andAmy J. Zigler
STI 571 (formerly known as CGP 57148B)
is a known inhibitor of the c-abl, bcr-abl,
and platelet-derived growth-factor recep-
tor (PDGFR) tyrosine kinases. This com-
pound is being evaluated in clinical trials
for the treatment of chronic myelogenous
leukemia. We sought to extend the activ-
ity proﬁle of STI 571 by testing its ability
to inhibit the tyrosine kinase activity of
c-kit, a receptor structurally similar to
PDGFR. We treated a c-kit expressing a
human myeloid leukemia cell line, M-07e,
with STI 571 before stimulation with Steel
factor (SLF). STI 571 inhibited c-kit auto-
phosphorylation, activation of mitogen-
activated protein (MAP) kinase, and acti-
vation ofAkt without altering total protein
levels of c-kit, MAP kinase, or Akt. The
concentration that produced 50% inhibi-
tion for these effects was approximately
100 nmol/L. STI 571 also signiﬁcantly
decreased SLF-dependent growth of
M-07e cells in a dose-dependent manner
and blocked the antiapoptotic activity of
SLF. In contrast, the compound had no
effect on MAP kinase activation or cellu-
lar proliferation in response to granulo-
cyte-macrophage colony-stimulating fac-
tor. We also tested the activity of STI 571
in a human mast cell leukemia cell line
(HMC-1), which has an activated mutant
form of c-kit. STI 571 had a more potent
inhibitory effect on the kinase activity of
this mutant receptor than it did on
ligand-dependent activation of the wild-
type receptor. These ﬁndings show that
STI 571 selectively inhibits c-kit tyrosine
kinase activity and downstream activa-
tion of target proteins involved in cellular
proliferation and survival. This com-
pound may be useful in treating cancers
associated with increased c-kit kinase
activity. (Blood. 2000;96:925-932)
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Introduction
c-kit, a 145-kd transmembrane glycoprotein, is the normal cellular
homologue of the viral oncogene v-kit and a member of the
receptor tyrosine kinase subclass III family that includes receptors
for platelet-derived growth factor (PDGF), macrophage colony-
stimulating factor, and ﬂt3 ligand.1-3 The c-kit gene product is
expressed by hematopoietic progenitor cells, mast cells, germ cells,
interstitial cells of Cajal (ICC), and some human tumors.4-8 Studies
of mice with inactivating mutations of c-kit or its ligand, Steel
factor (SLF), demonstrated that normal functional activity of the
c-kit gene product is absolutely essential for maintenance of
normal hematopoiesis,9,10 melanogenesis,5 gametogenesis,11 and
growth and differentiation of mast cells and ICC.12-14We and others
showed that SLF is produced by human and murine hematopoietic
stromal cells, including endothelial cells, ﬁbroblasts, and bone
marrow–derived stromal cells.15,16 The biologic features of SLF
and c-kit were reviewed by Broudy17 and Lyman and Jacobsen.18
In addition to its importance in normal cellular physiologic
activities, c-kit plays a role in the biologic aspects of certain human
cancers, including germ cell tumors, mast cell tumors, gastrointes-
tinal stromal tumors (GIST), small-cell lung cancer, melanoma,
breast cancer, acute myelogenous leukemia (AML), and neuroblas-
toma.19-27 Proliferation of tumor cell growth mediated by c-kit
occurs either by a speciﬁc mutation of the c-kit polypeptide that
results in ligand-independent activation or by autocrine stimulation
of the receptor.21,23 In some types of tumors, inhibition of c-kit
activity reduces cellular proliferation, suggesting a role for use of
pharmacologic inhibitors of c-kit in the treatment of c-kit–
dependent malignancies.20,21,28,29
STI571(formerlyknownasCGP57148B),a2-phenylaminopy-
rimidine derivative, is a known inhibitor of the c-abl, bcr-abl, and
PDGF receptor (PDGFR) tyrosine kinases.30,31 This compound is
currently being evaluated in clinical trials for the treatment of
chronic myelogenous leukemia (CML).32,33 There is a close
homology between the kinase domains of PDGFR and c-kit.
Previous reports on other PDGFR kinase inhibitors noted that some
of these compounds can inhibit the kinase activity of c-kit.34,35
Therefore, we speculated that STI 571 would also potently inhibit
the kinase activity of c-kit. Using biochemical and cell-based
assays of receptor activation, signal transduction, proliferation, and
apoptosis, we found that STI 571 inhibited the SLF-dependent
activation of wild-type c-kit kinase activity. The concentration that
produced 50% inhibition (IC50) for these effects was approximately
100 nmol/L, which is similar to the concentration required for
inhibition of bcr-abl and PDGFR. We also performed similar
studies using a mast cell leukemia cell line, HMC-1, that expresses
a constitutively activated c-kit polypeptide.36,37 STI 571 had a more
potent inhibitory effect on the kinase activity of this mutant
receptor than it did on ligand-dependent activation of the wild-type
receptor. We conclude that STI 571 is a potent inhibitor of c-kit
kinase activity and may be useful in treating tumors that are partly
or completely dependent on c-kit for proliferation or survival.
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Cell culture
M-07e is a human myeloid leukemia cell line that is dependent on the
growth factors interleukin 3, granulocyte-macrophage colony-stimulating
factor (GM-CSF), or SLF (Sigma, St Louis, MO) for proliferation.38 These
cells, a generous gift of Dr Hal Broxmeyer (Indiana University School of
Medicine), were cultured in RPMI 1640 (Gibco-BRL, Rockville, MD)
supplemented with 10% fetal-calf serum (FCS) and 200 U/mLrecombinant
human GM-CSF (Immunex, Seattle, WA). HMC-1, a factor-independent
cell line derived from a patient with mast cell leukemia, expresses a
juxtamembrane mutant c-kit polypeptide that has constitutive kinase
activity.37,39,40 The HMC-1 cells were generously provided by Dr Joseph
Butterﬁeld (Mayo Clinic, Rochester, MN) and maintained in Dulbecco
modiﬁed Eagle medium (Gibco-BRL) supplemented with 10% FCS.
Reagents
Dr Elizabeth Buchdunger (Novartis Pharma, Basel, Switzerland) gener-
ously provided STI 571 for these experiments. Fresh stock solutions of
inhibitor (10 mmol/L) were made before each experiment by dissolving 5
mg STI 571 in 1 mLphosphate-buffered saline (PBS; Gibco-BRL).
Antibodies
An anti-c-kit monoclonal antibody was used at a dilution of 1:200 (Roche
MolecularBiochemicals,Indianapolis,IN).Anantiphosphotyrosine(anti-P-
Tyr) antibody (PY20) was used at a dilution of 1:1000 (Transduction
Laboratories, Lexington, KY). An antiphospho-p44/p42 mitogen-activated
protein (MAP) kinase antibody that identiﬁes MAP kinase phosphorylated
at threonine 202 and tyrosine 204 was used at a dilution of 1:1000 (New
England Biolabs, Beverly, MA). Antibodies to total MAP kinase and total
Akt (New England Biolabs) were both used at a dilution of 1:1000. An
antiphospho-Akt antibody that identiﬁes Akt phosphorylated at serine 473
was used at a dilution of 1:1000 (New England Biolabs). Peroxidase-
conjugated goat-antimouse antibody was used at a dilution of 1:5000 and
goat antirabbit antibody at a dilution of 1:10 000 (Pierce, Rockford, IL).
Protein lysates
M-07e cells were grown in serum-free RPMI 1640 at 37°C for approxi-
mately 18 hours before they were incubated for 90 minutes in the presence
of various concentrations of STI 571. The cells were then pelleted and
resuspended in 1 mL RPMI 1640. STI 571 was added to each tube to
achieve the same concentration used during the 90 minutes of preincuba-
tion. The cells were then incubated with inhibitor and growth factor (SLF
[Sigma Chemical, St Louis, MO] or GM-CSF) for 15 minutes at 37°C.
Subsequently, the cell pellets were lysed with 100 to 250 µLof protein lysis
buffer (50 mmol/L Tris, 150 mmol/L sodium chloride, 1% NP-40, and
0.25% deoxycholate, with addition of the inhibitors aprotinin, leupeptin,
pepstatin, phenylmethyl sulfonyl ﬂuoride, and sodium orthovanadate
[Sigma]). Western immunoblot analysis was performed as previously
described.41 Experiments with HMC-1 cells were performed in the same
way except that neither SLF nor GM-CSF was added.
Proliferation assays
Cells were added to 96-well plates at a density of 20 000 cells/well for
HMC-1 and 50 000 cells/well for M-07e. Experiments with M-07e were
performed with use of GM-CSF or SLF as a growth factor supplement.
Experiments using HMC-1 were performed without growth factor supple-
mentation. Proliferation at 48 hours was measured with an XTT-based assay
(Roche Molecular Biochemicals).
Apoptosis assays
Apoptosis at 48 or 72 hours was measured by using a ﬂow cytometric assay
that assessed staining of cells with annexin V labeled with ﬂuorescein
isothiocyanate, conjugated (FITC; Pharmingen, San Diego, CA), as well as
uptake of the vital stain 7-amino-actinomycin D (7-AAD; Sigma).42,43
Results
STI 571 inhibits kinase activity of wild-type and mutant
c-kit polypeptide
We used the factor-dependent human myeloid leukemia cell line
M-07e to test the ability of STI 571 to inhibit the kinase activity of
wild-type c-kit receptor. Lysates prepared from M-07e cells were
probed with an anti-P-Tyr speciﬁc antibody. In these experiments,
SLF-dependentactivationwasmeasuredbyreceptorautophosphory-
lation.44,45 No signiﬁcant c-kit autophosphorylation was observed
in the absence of SLF (Figure 1). Inhibition of SLF-induced c-kit
autophosphorylation by STI 571 was dose dependent, with com-
plete inhibition observed at both 10 and 1.0 µmol/L. Inhibition was
also apparent at a dose of 0.5 µmol/L, although limited c-kit
autophosphorylation still occurred. At an STI 571 dose of 0.1
µmol/L, c-kit activation was approximately 50% that in SLF-
stimulated cells not treated with inhibitor. Thus, we found that SLF
activates c-kit and that this activation was effectively inhibited by
doses of STI 571 in the range of 0.1 to 10 µmol/L.
To determine whether STI 571 modulated expression of c-kit
protein, the membrane was stripped and reprobed with an anti-c-kit
primary antibody. The total amount of expressed c-kit protein did
not change after exposure to STI 571 (Figure 1).Thus, STI 571 was
found to inhibit SLF-dependent c-kit autophosphorylation but not
expression of c-kit protein.
Activating mutations of c-kit have been found in several types
of human malignant disease, including mastocytosis and mast
cell leukemia, AML, GIST, and seminoma and dysgerminoma
tumors.22-24,46-49 These mutations occur in 2 distinct regions of the
cytoplasmic portion of the c-kit polypeptide—the juxtamembrane
domain and the kinase domain.22,46-48,50 The mutations result in
ligand-independent constitutive kinase activity.51-53 STI 571 func-
tions as a competitive inhibitor of adenosine triphosphate (ATP)
binding to the kinase domain; therefore, mutations that alter
receptor structure or function might abrogate the inhibitory effects
of STI 571 on c-kit kinase activity.
To test the efficacy of STI 571 in inhibiting the activity of
mutant forms of c-kit, we used a human mast cell leukemia cell line
(HMC-1) that expresses a constitutively activated c-kit polypep-
tide.37 Lysates prepared from HMC-1 cells were probed with an
Figure 1. STI 571 inhibits Steel factor (SLF)–dependent phosphorylation of
c-kit. Serum was withheld from M-07e cells overnight before they were pretreated
with various concentrations of STI 571 for 90 minutes. Cells were then treated with
vehicle (phosphate-buffered saline) or SLF (ﬁnal concentration, 200 ng/mL) for 15
minutes. Whole cell lysates were immunoblotted by using an antiphosphotyrosine
(anti-P-Tyr) antibody. The membrane was stripped and reprobed with a monoclonal
antibody speciﬁc for human c-kit. The arrow indicates the position of the 145-kd
isoform of c-kit. Representative results from 1 of 8 independent experiments
are shown.
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measuring autophosphorylation. As reported previously,37 c-kit
autophosphorylation was observed in the absence of SLF (Figure
2). Inhibition of c-kit autophosphorylation by STI 571 was dose
dependent, with complete inhibition observed at doses of 10 and
1.0 µmol/L. Nearly complete inhibition occurred at a dose of 0.1
µmol/L. Limited autophosphorylation of c-kit was observed when
STI 571 doses of 0.001 to 0.01 µmol/L were used. Thus, our study
showed that STI 571 not only inhibits the autophosphorylation of
the mutated c-kit receptor in HMC-1 cells but is also a more potent
inhibitor of this mutated receptor than it is of the wild-type c-kit
receptor. To determine whether STI 571 modulated expression of
c-kit protein, the membrane was stripped and reprobed with an
anti-c-kit antibody. There was no change in the expression of c-kit
protein in cells treated with STI 571 (Figure 2). Therefore, we
found that STI 571 decreases autophosphorylation of mutant c-kit
polypeptide by inhibiting c-kit kinase activity rather than by
down-regulating expression of c-kit protein.
STI 571 inhibits c-kit–dependent but not GM-CSF
receptor–dependent activation of MAP kinase
Treatment of hematopoietic cells with SLF or GM-CSF results in
activation of MAP kinase.54-56 We sought to test the speciﬁcity of
STI 571 by examining its effects on SLF-dependent and GM-CSF–
dependent activation of MAP kinase in M-07e cells. Complete
inhibition of SLF-dependent activation of MAP kinase occurred at
10-, 1.0-, and 0.5-µmol/Lconcentrations of STI 571 (Figure 3).At a
dose of 0.1 µmol/L STI 571, MAP kinase–activation levels were
signiﬁcantly lower than those in control SLF-stimulated cells.Total
MAP kinase expression was not altered by treatment with STI 571
(Figure 3).
To conﬁrm the speciﬁcity of STI 571, we examined the
compound’s effect on GM-CSF–dependent activation of MAP
kinase. At concentrations of 0.1 to 10 µmol/L, STI 571 did not
affect GM-CSF–induced MAP kinase activation in M-07e cells
(Figure 4). Moreover, treatment with STI 571 did not alter total
expression of MAP kinase. Thus, we found that STI 571 in-
hibits SLF-dependent but not GM-CSF–dependent activation of
MAPkinase.
To conﬁrm that STI 571 could inhibit signal-transduction events
downstream of an activated mutant form of c-kit, we treated
HMC-1 cells with various concentrations of inhibitor. Complete
inhibition of MAPkinase activation occurred at 10- and 1.0-µmol/L
concentrations of STI 571 (Figure 5). Partial inhibition was
observed at a dose of 0.1 µmol/L, and no inhibition occurred at a
dose of 0.01 µmol/L. Total MAP kinase expression was not altered
by treatment with STI 571 (Figure 5). Therefore, we found that STI
571 inhibits the kinase activity of this mutant form of c-kit and
blocks c-kit–dependent activation of MAPkinase.
STI 571 inhibits c-kit–dependent activation of Akt
SLF-dependent activation of the c-kit receptor results in activation
of phosphatidylinositol 3 kinase (PI3K).55,57 One of the down-
stream events of the PI3K signal-transduction cascade is phosphor-
ylation and resultant activation of the proto-oncogene Akt.58 To
assess the effect of STI 571 on this pathway, we probed lysates
from M-07e cells treated with SLF (with and without STI 571) with
an antibody speciﬁc for the activated (phosphorylated) form ofAkt.
At doses ranging from 1.0 to 10 µmol/L, STI 571 markedly
inhibited SLF-dependent Akt phosphorylation (Figure 6). Partial
Figure 2. STI 571 inhibits autophosphorylation of an activated mutant form of
c-kit. HMC-1 cells were treated with various concentrations of STI 571 for 90
minutes. Whole cell lysates were prepared and immunoblotted with an anti-P-Tyr
monoclonal antibody. The membrane was stripped and reprobed with a monoclonal
antibody speciﬁc for human c-kit. The arrow indicates the position of the 145-kd
isoform of c-kit. Representative results from 1 of 8 independent experiments
are shown.
Figure 3. STI 571 inhibits SLF-dependent activation of mitogen-activated
protein (MAP) kinase. Whole cell lysates of M-07e cells were prepared and
immunoblotted with a polyclonal antibody speciﬁc for the doubly phosphorylated
forms of p44 and p42 MAP kinase (Erk1 and Erk2). The membrane was stripped and
reprobed with an antibody for total p44 and p42 MAP kinase. The arrows indicate the
locations of p44 and p42 MAPkinase. Representative results from 1 of 8 independent
experiments are shown.
Figure 4. STI 571 does not inhibit granulocyte-macrophage colony-stimulating
factor (GM-CSF)–dependent activation of MAP kinase. Serum was withheld from
M-07e cells overnight. The cells were then pretreated with various concentrations of
STI 571 for 90 minutes before the addition of vehicle or GM-CSF (ﬁnal concentration,
200 U/mL) for 15 minutes. Whole cell lysates were immunoblotted with an antibody
speciﬁc for phospho-MAP kinase. The membrane was stripped and reprobed with an
antibody for total p44 and p42 MAP kinase. The arrows indicate the locations of p44
and p42 MAP kinase. Representative results from 1 of 2 independent experiments
are shown.
Figure 5. STI 571 inhibits c-kit–dependent activation of MAP kinase in HMC-1
cells. HMC-1 cells were treated with various concentrations of STI 571 for 90
minutes. Whole cell lysates were immunoblotted with an antibody speciﬁc for
phospho-MAP kinase. The membrane was stripped and reprobed with an antibody
for total p44 and p42 MAP kinase. The arrows indicate the locations of p44 and p42
MAP kinase. Representative results from 1 of 8 independent experiments are shown.
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571. The kinase inhibitor had no effect on the expression of total
Akt protein (Figure 6). Thus, STI 571 inhibited SLF-dependent
activation ofAkt but not expression of totalAkt protein.
To test whether STI 571 could inhibit mutant c-kit receptor
activation of the signal-transduction pathways leading to Akt, we
performed similar studies using HMC-1 cells. STI 571 in doses
ranging from 0.1 to 10 µmol/L strongly inhibitedAkt phosphoryla-
tion (Figure 7). In contrast, no inhibition occurred at a dose of 0.01
µmol/L. STI 571 had no effect on the expression of totalAkt protein
(Figure 7). Therefore, the observed decrease in phosphorylatedAkt
protein was found to be a result of inhibition of Akt activation and
not due simply to an effect on total cellular Akt expression. Thus,
we conclude that STI 571 inhibition of mutant c-kit kinase activity
blocks both MAPkinase activation andAkt activation.
STI 571 inhibits c-kit–dependent proliferation but not GM-CSF
receptor–dependent proliferation
Proliferation assays were conducted to study the effect of STI 571
on both SLF-dependent and GM-CSF–dependent proliferation of
M-07e cells. At inhibitor concentrations of 10 and 1.0 µmol/L,
SLF-inducedproliferationwassigniﬁcantlydecreased,by97.6% 6
6.0% and 94.7% 6 5.3%, respectively, compared with that of cells
treated with SLF but not STI 571 (Figure 8). With 0.1 µmol/L STI
571, cellular proliferation was reduced by 59.9% 6 7.0%, and with
0.01 µmol/L, proliferation was decreased by 11.5% 6 4.8%. The
decrease in proliferation in the presence of 0.1 to 10 µmol/L
inhibitor was signiﬁcant (P # .001).
To test the speciﬁcity of STI 571 further, we measured the
proliferation of GM-CSF–stimulated M-07e cells in the presence
and absence of STI 571. Proliferation was not signiﬁcantly af-
fected by the addition of STI 571, even at a dose of 10 µmol/L
(Figure 9).Thus, we demonstrated that STI 571 selectively inhibits
SLF-dependent but not GM-CSF–dependent proliferation of
M-07e cells.
To test the biologic effect of inhibiting the kinase activity of a
mutant c-kit receptor, we cultured HMC-1 cells for 48 hours in the
presence of various concentrations of STI 571. At inhibitor
concentrations of 0.1 to 10 µmol/L, proliferation was decreased by
90% to 95% compared with results in cells treated with medium
only (Figure 10). Partial inhibition of proliferation occurred at a
dose of 0.01 µmol/L STI 571, and no inhibition was observed at a
dose of 0.001 µmol/L (data not shown). The decrease in prolifera-
tion with doses of 0.01 to 10 µmol/L inhibitor was signiﬁcant
(P , .001). Therefore, these experiments showed that STI 571
inhibits proliferation of HMC-1 cells with the same dose-response
Figure 6. STI 571 inhibits SLF-dependent activation of Akt. Whole cell lysates of
M-07e cells were prepared and immunoblotted with a polyclonal antibody speciﬁc for
Akt protein that had been activated by phosphorylation of serine 473. The membrane
was stripped and reprobed with an antibody to totalAkt. Representative results from 1
of 8 independent experiments are shown.
Figure 7. STI 571 inhibits c-kit–dependent activation of Akt in HMC-1 cells.
Whole cell lysates of M-07e cells were prepared and immunoblotted with a polyclonal
antibody speciﬁc forAkt protein that had been activated by phosphorylation of serine
473. The membrane was stripped and reprobed with an antibody to total Akt.
Representative results from 1 of 8 independent experiments are shown.
Figure 8. STI 571 inhibits SLF-dependent proliferation of M-07e cells. Serum
was withheld from M-07e cells overnight before they were used in proliferation
assays. Cells were plated in a 96-well plate at a concentration of 50 000 cells/well and
grown in RPMI-1640 supplemented with 10% fetal-calf serum (FCS) with and without
200 ng/mLSLF. STI 571 was added at the same time as SLF. Proliferation at 48 hours
was measured with an XTT-based assay system. Results are expressed as the
percentage of maximal proliferation (SLF only) (6 SD). Representative results from 1
of 6 independent experiments are shown.
Figure 9. STI 571 has no effect on GM-CSF–dependent proliferation of M-07e
cells. Serum was withheld from M-07e cells overnight before they were used in
proliferation assays. Cells were plated in a 96-well plate at a concentration of 50 000
cells/well and grown in RPMI-1640 supplemented with 10% FCS with and without
200 U/mLGM-CSF. STI 571 was added at the same time as GM-CSF. Proliferation at
48 hours was measured with an XTT-based assay system. Results are expressed as
the percentage of maximal proliferation (GM-CSF only) (6 SD). Representative
results from 1 of 2 independent experiments are shown.
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MAPkinase activation, andAkt activation.
STI 571 abrogates the antiapoptotic effect of c-kit activation
The effects of SLF on hematopoietic progenitors are both mito-
genic and antiapoptotic.59,60 The mechanism by which c-kit activa-
tion prevents apoptosis is unknown but may involve PI3K-
dependent activation of Akt.61,62 In our proliferation assays, we
observed not only a decrease in proliferation but also morphologic
features consistent with cellular death (data not shown). Because of
these morphologic observations and our earlier ﬁnding that STI
571 inhibited SLF-dependent activation of Akt, we hypothesized
that STI 571 would block the antiapoptotic effects of SLF.
To test our hypothesis, we withheld serum and growth factor
from M-07e cells for 24 hours before treating the cells with either
complete medium (10% FCS and GM-CSF), RPMI and 1% bovine
serum albumin (BSA) with and without SLF (200 ng/mL), or
RPMI, 1% BSA, and SLF, and various doses of STI 571.Apoptosis
was assessed 24 and 48 hours later by using a ﬂow cytometric assay
to measure cellular binding of an annexin V–FITC conjugate, as
well as uptake of the vital stain 7-AAD.42 Consistent with ﬁndings
of previous studies,38 the M-07e cells underwent apoptosis after
removal of speciﬁc hematopoietic growth factors (Table 1). Apop-
tosis could be prevented by adding GM-CSF or SLF. However,
simultaneous addition of SLF and STI 571 at doses of 10 or 1
µmol/L resulted in abrogation of the antiapoptotic effect of SLF.
The addition of STI 571 at a dose of 0.1 µmol/Lhad no effect on the
ability of SLF to prevent apoptosis.
HMC-1 cells treated with STI 571 underwent morphologic
changes consistent with cellular death.To test whether STI 571 was
inducing programmed cell death in these cells, we treated the
HMC-1 cells for 72 hours with various doses of inhibitor.
Apoptosis was assessed with a ﬂow cytometric assay as described
above. In doses of 1 to 10 µmol/L, STI 571 potently induced
apoptosis in HMC-1 cells. A less potent effect was observed at a
dose of 0.1 µmol/L (Table 2), and there was no effect on apoptosis
at a dose of 0.01 µmol/L. We conclude that the survival and
proliferation of HMC-1 cells depends on the kinase activity of the
mutant c-kit polypeptide.
Discussion
STI 571 was identiﬁed previously as a potent inhibitor of the c-abl
protein kinase and shown to have similar activity against v-abl and
both the p210 and p190 forms of bcr-abl.31,63,64 Additionally, STI
571 was found to inhibit the kinase activity of the a and b chains of
PDGFR.30,31,64 Experiments using cell-based assay systems re-
vealed that the IC50 for inhibition of these enzymes was 0.2 to 0.3
µmol/L. The selectivity of STI 571 was conﬁrmed by testing its
activity against a panel of protein kinases. For example, the IC50
was above 100 µmol/L for the kinase activity of epidermal growth
factor receptor, ﬁbroblast growth factor receptor, insulin-like
growth factor-1 receptor, v-src, c-fgr, c-lyn, v-fms, protein kinase
A, various protein kinase C isoforms, casein kinases 1 and 2, and
cdc2.30,31 In murine xenograft models of human CML, STI 571 was
conﬁrmed to have signiﬁcant antitumor activity, with minimal
toxicity.31 Currently, this compound is being evaluated in clinical
trials for the treatment of CML.32,33
In our studies of cells expressing wild-type c-kit protein, we
found that STI 571 potently inhibited the activity of c-kit kinase
activity, resulting in inhibition of autophosphorylation. Inhibition
of receptor kinase activity markedly decreased activation of MAP
kinase and a PI3K-dependent enzyme (Akt). STI 571 had no effect
on total cellular expression of c-kit, Erk-1, Erk-2, orAkt.Treatment
of M-07e cells with STI 571 inhibited SLF-dependent but not
GM-CSF–dependent proliferation and abrogated the antiapoptotic
Table 1. Effect of STI 571 on the antiapoptotic effect of Steel factor (SLF)
on M-07e cells
Condition
Early
apoptosis
(% of stained cells)
Late
apoptosis
(% of stained cells)
10% fetal-calf serum (FCS) 1 GM-CSF 4.4 1.8
1% bovine serum albumin (BSA) 18.9 11.9
SLF 10.4 4.5
SLF 1 10 µmol/L STI 571 20.8 12.2
SLF 1 1 µmol/L STI 571 20.5 11.3
SLF 1 0.1 µmol/L STI 571 10.8 4.5
GM-CSF indicates granulocyte-macrophage colony-stimulating factor. Serum
and growth factor were withheld from M-07e cells for 24 hours before the cells were
treated with either complete medium (10% FCS and GM-CSF), RPMI and 1% BSA
with and without SLF (200 ng/mL), or RPMI, 1% BSA, and SLF, and various doses of
STI 571. Apoptosis at 48 hours was assessed by using a ﬂow cytometric assay to
measure cellular binding of a conjugate of annexin V and ﬂuorescein isothiocyanate,
conjugated (FITC), as well as uptake of the vital stain 7-amino-actinomycin D
(7-AAD). A total of 10 000 cells were analyzed for each condition. Results are
expressed as the percentage of cells that stained positively for annexin V-FITC only
(early apoptosis) or for both annexin V-FITC and 7-AAD (late apoptosis). Representa-
tive results from 1 of 3 independent experiments are shown.
Table 2. Effect of STI 571 on apoptosis in HMC-1 cells
Condition
Early apoptosis
(% of stained cells)
Late apoptosis
(% of stained cells)
Medium only 3.6 5.7
10 µmol/L STI 571 52.7 31.9
1 µmol/L STI 571 63.7 32.0
0.1 µmol/L STI 571 30.7 13.2
0.01 µmol/L STI 571 4.9 4.3
HMC-1 cells were grown in RPMI-1640 and 10% FCS with and without various
concentrations of STI 571. Apoptosis at 72 hours was assessed by using a ﬂow
cytometric assay to measure cellular binding of an annexin V–FITC conjugate, as
well as uptake of the vital stain 7-AAD.Atotal of 10 000 cells were analyzed for each
condition. Results are expressed as the percentage of cells that stained positively for
annexin V-FITC only (early apoptosis) or for both annexin V-FITC and 7-AAD (late
apoptosis). Representative results from 1 of 4 independent experiments are shown.
Figure 10. STI 571 inhibits proliferation of HMC-1 cells. HMC-1 cells were plated
in 96-well plates at a concentration of 20 000 cells/well and cultured in RPMI-1640
supplemented with 10% FCS with and without various concentrations of STI 571.
Cellular proliferation at 48 hours was measured with an XTT-based assay system.
Results are expressed as the percentage of maximal proliferation (cells only; no STI
571) (6 SD). Representative results from 1 of 6 independent experiments are shown.
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about 100 nmol/L, which is similar to the IC50 of 100 to 300 nmol/L
observed with use of bcr-abl or PDGFR as a target.
Because of its structure, c-kit is classiﬁed as a type III receptor
tyrosine kinase. All members of this family have an extracellular
domain containing 5 immunoglobulin-like domains, a single
transmembrane domain, and a cytoplasmic domain with a split
kinase domain and a hydrophilic kinase insert sequence.17 The
juxtamembrane and kinase domains of these receptors are strongly
conserved.35 Interestingly, STI 571 can inhibit the kinase activity of
c-kit, PDGFRa, and PDGFRb but has no effect on the kinase
activity of the related receptor tyrosine kinases c-fms and ﬂk2/ﬂt3
(data not shown).31,64,65
c-kit has been implicated in the pathophysiologic mechanisms
of a variety of human tumors, including mastocytosis and mast cell
leukemia, testicular cancer, small-cell lung cancer, GIST, AML,
neuroblastoma, melanoma, and breast cancer. Two general mecha-
nisms of c-kit activation in malignant cells have been described: (1)
autocrine or paracrine stimulation of the receptor by SLF, and (2)
acquisition of activating mutations.8,21-23,26-28,66-69
Autocrine or paracrine stimulation of c-kit has been observed in
some human cancers, including neuroblastoma and small-cell lung
cancer.20,21,28 Experimental approaches to demonstrating the role of
the SLF–c-kit axis in cancer cell biology have been hampered by
the lack of a speciﬁc way to inhibit c-kit signal transduction.
Previous studies used reagents such as the tyrphostinsAG1295 and
AG1296 to inhibit c-kit kinase activity. These studies, however,
were limited by the poor solubility of these compounds in cell
culture media and by variable speciﬁcity.29,34 Other approaches for
inhibiting c-kit experimentally included use of antisense oligo-
nucleotides, transfection of dominant negative c-kit constructs, and
antibodies that neutralize the c-kit ligand-binding site. The ﬁrst 2
techniques are limited by delivery efficiency and the inability to
totally inhibit c-kit expression or activity.20,70,71 Use of neutralizing
antibodies is constrained by the binding affinity of the antibody.
Additionally, autocrine stimulation of receptor by its cognate
ligand can, at least in some cases, occur intracellularly and thus
cannot be inhibited by extracellular antibody.72 In this study, we
found that STI 571 speciﬁcally inhibits c-kit, in addition to its
previously reported effects on PDGFR, c-abl, v-abl, and bcr-abl.
Thus, this compound may be useful in vitro for deﬁning the role of
the SLF–c-kit axis in tumor cell proliferation.
Activating mutations of c-kit have been described in cases of
human mast cell disorders, seminoma, and GIST.22,23,46,47,73 For
mast cell disorders and GIST, the presence of the c-kit mutation, the
type of mutation, or both, has clinical prognostic impor-
tance.24,46,73,74 Interestingly, these tumors arise in tissue types (mast
cells, germ cells, and ICC) whose development depends on the
activity of the SLF–c-kit axis. Indeed, these cells are absent in mice
with inactivating mutations of either SLF or c-kit.5,13,14,75 The
development of tumors in these tissues may require either mutation
of c-kit or an alternative way to activate the downstream effectors
of c-kit signal transduction.
Pharmacologic inhibition of c-kit is a potential novel approach
to treatment of malignancies that are partly or completely depen-
dent on the activity of an activated c-kit receptor.Although current
medical treatments for seminoma are curative for most patients,
there are no effective medical treatments for patients with advanced
mast cell disease or recurrent or metastatic GIST.76,77 Indeed, a
1999 retrospective review of chemotherapy for GIST found a
response rate of less than 10%.78
We used the HMC-1 cell line to test the ability of STI 571 to
inhibit the kinase activity of a mutant form of c-kit. This
factor-independent cell line was originally derived from a patient
with mast cell leukemia and expresses a constitutively activated
c-kit protein.37,40 In our studies, STI 571 potently inhibited receptor
autophosphorylation, MAP kinase activation, and Akt activation
without affecting levels of c-kit, Erk-1, Erk-2, orAkt.Additionally,
doses of 0.01 to 10 µmol/L STI 571 inhibited HMC-1 cellular
proliferation. HMC-1 cells appear to be strongly dependent on the
activity of the mutant receptor to prevent apoptosis, since 85% to
95% of cells exposed to 1 to 10 µmol/L STI 571 for 48 to 72 hours
underwent programmed cell death. The IC50 for induction of
apoptosis was approximately 0.1 µmol/L. Thus, STI 571 can
potently inhibit the kinase activity of the mutant c-kit polypeptide
expressed by HMC-1 cells. The effect of STI 571 on receptor
activation was even more potent than that observed when the
wild-type c-kit receptor was used as a target. It is unknown whether
this particular c-kit mutation actually increases the sensitivity of
the kinase domain to inhibition by the compound or whether the
observed differences in kinase sensitivity resulted from unrelated
factors, such as differential cellular uptake of the compound.
On the basis of these studies, we propose that STI 571 may be
useful for treatment of malignancies that are completely or partly
dependent on the activity of wild-type or mutant c-kit for prolifera-
tion or survival. In phase I and II clinical trials of treatment of
patients with CML, STI 571 was effective and well tolerated.32,33 In
these trials, trough levels of 1 µmol/L were readily obtained in
patients, and this level of STI 571 is an order of magnitude greater
than the IC50 for inhibition of c-kit (B. Druker, unpublished data,
March 2000). Further studies are warranted to determine the
potential efficacy of inhibiting c-kit kinase activity as a novel
strategy for treatment of human cancers.
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